Parren
Universiteit Leiden
H-index: 102
Europe-Netherlands
Top articles of Parren
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Heterodimeric antibody Fc-containing proteins and methods for production thereof | 2024/1/9 | ||
Antibodies against cd38 for treatment of multiple myeloma | 2024/4/25 | ||
Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells | Cancer Gene Therapy | Willemijn van der Wulp Dennis FG Remst Michel GD Kester Renate S Hagedoorn Paul WHI Parren | 2024/1 |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof | 2023/12/14 | ||
Multispecific antibodies against CD40 and CD137 | 2023/3/23 | ||
Antibodies binding axl | 2022/9/30 | ||
Monoclonal antibodies against c-met | 2024/1/17 | ||
Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation | Proceedings of the National Academy of Sciences | Douwe J Dijkstra Fleur S van de Bovenkamp Leoni Abendstein Rob Zuijderduijn Jos Pool | 2023/12/12 |
ANTICUERPOS PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS (Divisional expediente 2018-0021) | 2023/8/25 | ||
Human monoclonal antibodies against interleukin 8 (il-8) | 2023/2/9 | ||
Inert format | 2023/10/12 | ||
Binding agents binding to pd-l1 and cd137 and use thereof | 2023/3/23 | ||
Anticorpo humanizado ou quimérico de ligação ao cd3 humano, anticorpo biespecífico, microrganismo, composição, composição farmacêutica, uso dos mesmos, método para produzir um … | 2023/12/5 | ||
Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer | 2023/8/17 | ||
99 Targeted complement inhibition using engineered bispecific antibodies that bind local antigens and endogenous complement regulators as a novel therapeutic approach | Immunobiology | Leendert Trouw Douwe Dijkstra Leoni Abendstein Kyra Gelderman Paul Parren | 2023/9/1 |
TREATMENT OF CANCER COMPRISING ADMINISTRATION OF Vg9Vd2 T CELL RECEPTOR BINDING ANTIBODIES | 2023/2/2 | ||
Axl-specific antibody-drug conjugates for cancer treatment | 2023/10/12 | ||
Humanized or chimeric cd3 antibodies | 2023/11/23 | ||
Production of heterodimeric proteins | 2023/7/20 | ||
A bispecific T cell engager recruits both type 1 NKT and Vy9V52-T cells for the treatment of CD1d-expressing hematological malignancies | Cell Reports Medicine | Roeland Lameris Jurjen M Ruben Victoria Iglesias-Guimarais M de Jong Myrthe Veth | 2023/3/21 |
Co-Authors
